Jaguar Health Announces Adjournment of Special Meeting of Stockholders Until Friday, December 15, 2017
The Special Meeting has been adjourned to
During the period of the adjournment, Jaguar will continue to solicit
proxies from its stockholders with respect to the proposals set forth in
the proxy statement. Only stockholders of record on the record date of
The Company encourages all stockholders who have not yet voted to do so
How You Can Vote
The stockholders may vote by internet at www.investorvote.com/JAGX,
or by telephone at 800-652-VOTE (8683) within the
No changes have been made to the proposals to be voted on by
stockholders at the Special Meeting. The Company's proxy statement and
any other materials filed by the Company with the
The Board and management of Jaguar recommend that you vote FOR the approval of each of the proposals before the stockholders at the Special Meeting.
This material may be deemed to be solicitation material in respect of
the solicitation of proxies from stockholders in connection with the
Special Meeting. Jaguar has filed with the
Mytesi® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com.
Crofelemer, the active ingredient in Mytesi®, is a botanical
(plant-based) drug extracted and purified from the red bark sap of the
medicinal Croton lechleri tree in the
Certain statements in this press release constitute “forward-looking statements.” These include statements regarding planned, potential follow-on indications for Mytesi®. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar’s control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Jaguar Health, Inc.